Company: AbbVie
Posted by SkyriziGI_ABBV · March 22, 2026
Tags: pipeline, territory
One year into the Skyrizi IBD launch and I'm cautiously optimistic.
GI specialists who were Stelara loyalists are starting to look at the data more seriously.
The SEQUENCE head-to-head data helps a lot in those conversations.
Pull-through for infusion has been smoother than the Rinvoq IBD launch a few years back.
The main challenge remains identifying the right newly diagnosed patients before they get defaulted to Stelara or Humira biosimilars by their system protocols.
The account management work is critical here — you have to be in the formulary conversation early.
Reps who are good at health system navigation are thriving.
38 upvotes · 0 comments